Navigation Links
Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
Date:5/20/2008

- Study shows significantly improved bronchodilation and symptom control

with combination therapy -

NAPA, Calif., May 20 /PRNewswire/ -- A newly published study presents data demonstrating that patients with Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, experienced markedly improved bronchodilation and symptom control when treated with a combination of nebulized formoterol fumarate inhalation solution (Perforomist(TM) Inhalation Solution) and tiotropium (TIO), compared to treatment with tiotropium alone. The two medications, when used adjunctively, were also well tolerated by patients over the course of the 6-week study.

"Concomitant Treatment with Nebulized Formoterol and Tiotropium in Subjects with COPD: A Placebo-Controlled Trial," published in Respiratory Medicine, assesses the efficacy and safety of the concomitant treatment of Perforomist(TM) nebulized formoterol fumarate (a long-acting beta-agonist [LABA]) and tiotropium (an anticholinergic) in 130 adults with moderate to severe COPD.

"These data provide additional insight into the additive benefit of concomitant therapy with a LABA and a long-acting anticholinergic," said Dr. Donald Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles, lead author and principal investigator of the study. "When Perforomist(TM) Solution's rapid onset of action is combined with tiotropium's prolonged bronchodilation, the result appears to be a safe and effective treatment option for patients. This is great news for the millions of patients -- and their families -- who live with COPD, and who too often struggle with an insufficient number of robust treatment options."

About the Study

The study was a six-week, randomized, double-blind, placebo-controlled, parallel-group design study. COPD patients entered a 7-14 day run-in period during which subje
'/>"/>

SOURCE Dey, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
2. Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
3. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
4. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
5. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
6. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
10. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   3D Systems   (NYSE: DDD ) ... , a new robotic surgery skills and procedural training simulator, ... ERUS exhibition in Amsterdam, The Netherlands ... minimally invasive surgery represents a growing portion of overall surgical ... for robotic surgery has increased, and it is expected that ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker discovery ... US trial of its MiStat™ prostate cancer screening test, ... regulatory approval upon completion. Minomic,s proprietary MiStat™ ... presence of a proprietary biomarker known as the MIL-38 ... prostate cancer cells. Researchers at 11 ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... EATONTOWN, N.J. , Jan. 14 Osteotech, Inc. (Nasdaq: ... products for regenerative healing, today reported preliminary unaudited revenue for the ... $24.6 million for the same period in 2008.  During ... revenue from sales of its new innovative products all currently in ...
... and NORTH BRUNSWICK, N.J. , Jan. 14 ... that they have achieved the initial milestone of a research ... vitro test for potential allergic reactions to substances that could ... "Allergy Test on a Chip™," is intended to comprise a ...
Cached Medicine Technology:Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 2Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 3Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 4L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 2L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 3
(Date:9/18/2014)... is good for you. But new research from University ... added benefit for cancer patients undergoing chemotherapy. , Their ... that combining exercise with chemotherapy shrunk tumors more than ... in the School of Nursing and director of the ... senior author on the study, which appears in the ...
(Date:9/18/2014)... September 18, 2014 TayganPoint Consulting ... today that President and co-founder John Cassimatis was ... Award Winners for 2014, recognizing the region’s top ... an emerging executive of the year. , The ... life sciences that continue to shape the medical ...
(Date:9/18/2014)... September 18, 2014 Ben Quirk, CEO ... Ormond, Jr. Leadership Award by the Savannah Science Seminar ... and wellness throughout the nation and especially in Savannah. ... award,” said Ben. “The Savannah Science Seminar is an ... and multiple generations have gone through the program,” he ...
(Date:9/18/2014)... new method to study Ebola virus in wildlife. Video ... (WCS)-led research, published today in the journal PLOS ... samples from wild great apes to identify populations likely ... a new tool for performing large, population-scale field assessments ... studied and improve our understanding of the virus, distribution ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded the ... grant to the Los Angeles Biomedical Research Institute (LA ... a vaccine to protect patients from the healthcare-related infections, ... (MRSA). , The National Institute of Allergy and ... to LA BioMed infectious disease specialists John E. Edwards, ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... ITASCA, Ill., March 20 Arthur J. ... Healthcare Risk Solutions, LLC,headquartered in Fort Washington, ... Founded in 2002, Healthcare Risk Solutions, ... professional liability insurance,products, associated risk mitigation consulting ...
... PRGO ; TASE) today announced that the ... Jersey has denied Connetics Corporation,s motion,for a preliminary ... generic equivalent to Connetics, Olux(R) Foam and has,lifted ... launching,the product. The Court also denied Perrigo,s motion ...
... emotional well-being, study suggests , , THURSDAY, March 20 (HealthDay ... health of the husband -- as either patient or ... of mind, new research suggests. , The finding suggests ... his wife,s experience of psychological distress more so than ...
... WASHINGTON, March 20 Veterans in seven,additional states ... Department of Veterans Affairs (VA) plan to open 14 ... James B. Peake today,announced that VA will establish new ... "VA is dedicated to providing the best in ...
... was a rainy,Saturday, nothing could dampen the spirits ... Free Families (DCTFF) hosted a special evening at,Saturday,s ... over 100 D.C.,residents who have quit smoking using ... Health Care, Inc., (Photo: http://www.newscom.com/cgi-bin/prnh/20080320/NETH063 ...
... halve by 2015 the number of people without toilet access ... every dollar spent installing toilets in developing countries, there would ... according to a UN report released today. , The UN ... 2015 the number of people worldwide who don,t have access ...
Cached Medicine News:Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 2Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 3Health News:Cancer Poses Challenges for Husbands' Frame of Mind 2Health News:Cancer Poses Challenges for Husbands' Frame of Mind 3Health News:VA to Open 14 New Clinics in Seven States 2Health News:Quitters Honored at Wizards' DC Tobacco Free Family Night 2Health News:Cleaning Up the World's Sanitation 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: